Avillion LLP Company Profile
Avillion is a drug development company with an innovative business model for the clinical development and approval of late stage pharmaceutical products.
We offer a compelling opportunity to partner late phase therapeutic projects for approval in the EU and US and to accelerate their availability to the market.
Avillion is staffed with a team of expert professionals with extensive experience in the clinical development and regulatory approval of pharmaceutical products on a global basis.
Our offices are in London, United Kingdom, and we are financed by our international investors, Abingworth and Clarus Ventures.
News from Avillion LLP:
Avillion Group Partners with Pfizer to Co-develop BOSULIF® (bosutinib) as First-Line Treatment for Patients with Chronic Myelogenous Leukemia
LONDON, Jan. 9, 2014 /PRNewswire/ — The Avillion Group (Avillion), a co-developer of late-stage clinical assets, announced today that it has entered into an exclusive collaborative development agreement with Pfizer Inc. to conduct a global Phase 3 clinical trial of Pfizer’s BOSUL…
Avillion Expands Leadership Team with Appointment of Ramani Varanasi as Chief Business Officer
LONDON, May 28, 2013 /PRNewswire/ – Avillion LLP, which focuses on clinical co-development of therapeutics, today announced the expansion of its leadership team with the appointment of Ramani Varanasi, MSc, MBA, as Chief Business Officer.
Ramani is an accomplished business executive, bri…